Cholesterol-lowering drugs may reduce cardiovascular death in Type 2 diabetes

July 16, 2014 – Heart disease and stroke are the leading causes of death and disability among people with Type 2 diabetes. In fact, at least 65 percent of people with diabetes die from some form of heart disease or stroke, according to the American Heart Association.

However, a new study by researchers at Wake Forest Baptist Medical Center suggests that the use of cholesterol-lowering statins may help prolong the lives of people with diabetic .

The study is published in the current online edition of Diabetes Care.

"Although our study was not a clinical trial, it did show that people with diabetes and can still live quite a few years by taking statins," said Don Bowden, Ph.D., professor of biochemistry at Wake Forest Baptist and lead author of the study.

The research team studied data from 371 patients who had participated in the Diabetes Heart Study. At the beginning of the study, the participants received a CT scan to determine their levels of (CAC); a CAC score greater than 1,000 indicates an increased risk for cardiovascular disease (CVD).

The team compared the baseline characteristics of 153 patients who died during an average 8.2 years of follow-up and 218 who survived. The researchers assumed that risk for mortality would be consistently high among the study participants. However, 60 percent were still living after more than eight years.

The use of cholesterol-lowering statins at the baseline exam was the only modifiable risk factor identified to be protective against mortality. The participants taking statins at the beginning of the study had a 50 percent increase of being alive as compared to those who didn't.

Bowden said this highlights the importance of widespread prescription of cholesterol-lowering medications among individuals with Type 2 who have existing high CVD risk, but added that in previous studies the rates of statins prescribed for diabetic patients have been low.

"These data suggest that cholesterol-lowering medications may be used less than recommended and need to be more aggressively targeted as a critical modifiable risk factor," he said.

add to favorites email to friend print save as pdf

Related Stories

Modifiable risk factors impact CVD mortality in T2DM

Jul 14, 2014

(HealthDay)—Modifiable risk factors can be targeted for early and continued intervention to reduce the risk of adverse outcomes in patients with type 2 diabetes mellitus and cardiovascular disease, according ...

Recommended for you

Economic burden of prediabetes up 74 percent over five years

Nov 20, 2014

The economic burden of diabetes in America continues to climb, exceeding more than $322 billion in excess medical costs and lost productivity in 2012, or more than $1,000 for every American, according to a study being published ...

Gynoid fat resists metabolic risks of obesity

Nov 19, 2014

(HealthDay)—The differences in the developmental profiles of upper-body and lower-body fat depots may explain their opposing associations with obesity-related metabolic disease, according to research published ...

Treating diabetes one meal at a time

Nov 19, 2014

Recent estimates project that as many as one in three American adults will have diabetes in 2050. The American Diabetes Association observes November as American Diabetes Month, and this year's theme is America ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.